Get the Stockscreener App
25.98
0.74%
0.19
After Hours:
25.64
-0.34
-1.31%
Beam Therapeutics Inc stock is traded at $25.98, with a volume of 1.99M.
It is up +0.74% in the last 24 hours and up +15.72% over the past month.
Beam Therapeutics Inc is a biotechnology company committed to creating a new class of precision genetic medicines based on its proprietary base editing technology, with a vision of providing lifelong cures to patients suffering from serious diseases. The company is focused on its programs in the hematology and genetic disease portfolios, which comprise different product candidates in its pipeline, such as BEAM-101, which is being developed to target Sickle Cell Disease, BEAM-302, a liver-targeting lipid nanoparticle, being developed to target Alpha-1 antitrypsin deficiency, and other drug candidates including BEAM-302, BEAM-103 & 104. The company views its operations and manages its business in one operating segment, operating exclusively in the United States.
See More
Previous Close:
$25.79
Open:
$25.47
24h Volume:
1.99M
Relative Volume:
0.78
Market Cap:
$2.63B
Revenue:
$352.57M
Net Income/Loss:
$-143.01M
P/E Ratio:
-14.35
EPS:
-1.81
Net Cash Flow:
$-153.40M
1W Performance:
-1.29%
1M Performance:
+15.72%
6M Performance:
+52.82%
1Y Performance:
+6.69%
1-Day Range:
$25.29
$26.38
1-Week Range:
$23.53
$28.48
52-Week Range:
$13.53
$35.25
Beam Therapeutics Inc Stock (BEAM) Company Profile
Name
Beam Therapeutics Inc
Sector
Industry
Phone
857-327-8775
Address
26 LANDSDOWNE STREET, CAMBRIDGE, MA
Compare BEAM with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
BEAM
Beam Therapeutics Inc
|
25.98 | 2.61B | 352.57M | -143.01M | -153.40M | -1.81 |
|
VRTX
Vertex Pharmaceuticals Inc
|
416.81 | 104.76B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
481.67 | 63.06B | 2.46B | -319.09M | -52.09M | -2.4669 |
|
REGN
Regeneron Pharmaceuticals Inc
|
578.05 | 60.32B | 14.21B | 4.46B | 3.56B | 39.69 |
|
ARGX
Argen X Se Adr
|
843.66 | 51.55B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
165.76 | 34.49B | 398.11M | -1.03B | -868.57M | -5.7032 |
Beam Therapeutics Inc Stock (BEAM) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Oct-09-25 | Initiated | Jefferies | Buy |
| Mar-28-25 | Upgrade | BofA Securities | Neutral → Buy |
| Mar-10-25 | Upgrade | Scotiabank | Sector Perform → Sector Outperform |
| Jan-29-25 | Upgrade | Cantor Fitzgerald | Neutral → Overweight |
| Nov-06-24 | Upgrade | Leerink Partners | Market Perform → Outperform |
| Oct-16-24 | Initiated | Scotiabank | Sector Outperform |
| Jul-23-24 | Initiated | H.C. Wainwright | Buy |
| Jan-29-24 | Upgrade | JP Morgan | Neutral → Overweight |
| Dec-15-23 | Downgrade | BofA Securities | Buy → Neutral |
| Dec-08-23 | Downgrade | Jefferies | Buy → Hold |
| Oct-20-23 | Downgrade | Cantor Fitzgerald | Overweight → Neutral |
| Oct-20-23 | Downgrade | Leerink Partners | Outperform → Market Perform |
| Mar-21-23 | Initiated | Bernstein | Mkt Perform |
| Feb-01-23 | Initiated | Cantor Fitzgerald | Overweight |
| Dec-20-22 | Upgrade | BMO Capital Markets | Market Perform → Outperform |
| Dec-13-22 | Initiated | Citigroup | Buy |
| Jun-17-22 | Initiated | BMO Capital Markets | Market Perform |
| Apr-28-22 | Initiated | Credit Suisse | Neutral |
| Jan-05-22 | Initiated | Guggenheim | Buy |
| Oct-19-21 | Initiated | SVB Leerink | Outperform |
| Sep-24-21 | Resumed | Stifel | Buy |
| Sep-10-21 | Initiated | BofA Securities | Buy |
| May-11-21 | Initiated | Redburn | Buy |
| May-04-21 | Initiated | RBC Capital Mkts | Sector Perform |
| Mar-01-21 | Downgrade | Barclays | Overweight → Equal Weight |
| Feb-16-21 | Initiated | Wells Fargo | Overweight |
| Jan-29-21 | Downgrade | JP Morgan | Overweight → Neutral |
| Jan-06-21 | Initiated | Stifel | Hold |
| Aug-05-20 | Initiated | William Blair | Outperform |
| Mar-02-20 | Initiated | Barclays | Overweight |
| Mar-02-20 | Initiated | JP Morgan | Overweight |
| Mar-02-20 | Initiated | Jefferies | Buy |
| Mar-02-20 | Initiated | Wedbush | Outperform |
View All
Beam Therapeutics Inc Stock (BEAM) Latest News
What analyst consensus says on Beam Therapeutics Inc. stockWeekly Volume Report & Step-by-Step Swing Trade Plans - newser.com
Technical analysis overview for Beam Therapeutics Inc. stockEntry Point & AI Driven Stock Reports - newser.com
Wall Street Analysts Think Beam Therapeutics (BEAM) Could Surge 76.15%: Read This Before Placing a Bet - sharewise.com
Is Beam Therapeutics (BEAM) Stock Outpacing Its Medical Peers This Year? - sharewise.com
Why Beam Therapeutics Inc. stock is favored by pension fundsRate Hike & Growth Oriented Trading Recommendations - newser.com
Should you wait for a breakout in Beam Therapeutics Inc.Weekly Market Summary & Safe Capital Growth Tips - newser.com
Visualizing Beam Therapeutics Inc. stock with heatmapsEarnings Miss & Expert Verified Movement Alerts - newser.com
Published on: 2025-10-15 09:56:45 - newser.com
What the charts say about Beam Therapeutics Inc. todayMarket Sentiment Report & Real-Time Buy Signal Notifications - newser.com
Sickle Cell Disease Pipeline Insights Report 2025: DelveInsight Highlights Cutting-Edge Treatments and Clinical Progress - The Globe and Mail
Beam Therapeutics Experiences Revision in Stock Evaluation Amid Market Dynamics - Markets Mojo
Beam Therapeutics (BEAM): Assessing Valuation After Fresh Buy Ratings, Clinical Updates, and Institutional Moves - Yahoo Finance
Jim Cramer on Beam Therapeutics: “That’s the Speculative Bottom There” - MSN
Beam Therapeutics (NASDAQ:BEAM) Earns "Buy" Rating from HC Wainwright - MarketBeat
Beam Therapeutics (NASDAQ:BEAM) Coverage Initiated by Analysts at Jefferies Financial Group - MarketBeat
Does Beam Therapeutics Inc. qualify in momentum factor screeningJuly 2025 Macro Moves & Long-Term Growth Portfolio Plans - newser.com
Bristol Myers Squibb buys Cambridge biotech for $1.5B - The Business Journals
HC Wainwright & Co. Reiterates Beam Therapeutics (BEAM) Buy Recommendation - Nasdaq
HC Wainwright & Co. Reiterates Buy Rating for BEAM at $80 Target - GuruFocus
Beam Therapeutics (NASDAQ:BEAM) Given "Sell (D-)" Rating at Weiss Ratings - MarketBeat
Beam Therapeutics Stock Soars 7.44%, Hits Intraday High of $27.55 - Markets Mojo
Jefferies initiates Beam Therapeutics stock with Buy rating on upcoming catalysts By Investing.com - Investing.com Canada
Jefferies initiates Beam Therapeutics stock with Buy rating on upcoming catalysts - Investing.com Canada
Jefferies Initiates Beam Therapeutics with "Buy" Rating, Eyeing Promising Gene-Editing Pipeline and Upcoming Catalysts - FinancialContent
Jefferies Initiates Beam Therapeutics at Buy Rating, $41 Price Target - MarketScreener
Does Beam Therapeutics Inc. show high probability of reboundEntry Point & Step-by-Step Swing Trade Plans - newser.com
SteelPeak Wealth LLC Invests $391,000 in Beam Therapeutics Inc. $BEAM - MarketBeat
Sector ETF performance correlation with Beam Therapeutics Inc.Product Launch & Low Risk Investment Opportunities - newser.com
Is Beam Therapeutics Inc. stock entering bullish territoryPortfolio Update Summary & Real-Time Volume Analysis - newser.com
Why Intellia Therapeutics’ Stock Could Be a Gene‑Editing Goldmine in 2025 – Deep Dive into NTLA’s Prospects - ts2.tech
Jim Cramer Sees More Upside For Shopify, Likes CoreWeave's AI Moves - Benzinga
What Does Wall Street Think About Beam Therapeutics (BEAM)? - Insider Monkey
Beam Therapeutics to Participate in Upcoming September 2025 Investor Conferences - FinancialContent
14 Biotech Stocks with High Potential - Insider Monkey
Using Ichimoku Cloud for Beam Therapeutics Inc. technicalsQuarterly Profit Summary & Low Risk Entry Point Tips - newser.com
Beam Therapeutics Inc Stock (BEAM) Financials Data
Revenue
Net Income
Cash Flow
EPS
Beam Therapeutics Inc Stock (BEAM) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Bellon Christine | Chief Legal Officer |
Oct 01 '25 |
Sale |
24.53 |
373 |
9,150 |
116,921 |
| Evans John M. | CEO |
Oct 01 '25 |
Option Exercise |
0.67 |
25,000 |
16,750 |
1,011,667 |
| Evans John M. | CEO |
Oct 02 '25 |
Option Exercise |
0.67 |
25,000 |
16,750 |
1,011,667 |
| Evans John M. | CEO |
Oct 02 '25 |
Sale |
24.63 |
25,000 |
615,668 |
986,667 |
| Evans John M. | CEO |
Oct 01 '25 |
Sale |
24.51 |
25,000 |
612,655 |
986,667 |
1.84%
0.50%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):